Ftse Mib
34.088,40
-0,84%
DAX
18.489,60
-0,59%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
62.547,12
-3,55%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

PCSA

Processa Pharmaceuticals (PCSA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA
DataOraFonteTitoloSimboloCompagnia
28/03/202413:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/03/202413:15GlobeNewswire Inc.Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingNASDAQ:PCSAProcessa Pharmaceuticals Inc
21/02/202423:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCSAProcessa Pharmaceuticals Inc
21/02/202414:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
14/02/202419:00GlobeNewswire Inc.Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
06/02/202414:30GlobeNewswire Inc.Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleNASDAQ:PCSAProcessa Pharmaceuticals Inc
02/02/202400:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
01/02/202422:22GlobeNewswire Inc.Processa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/01/202422:15Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
29/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PCSAProcessa Pharmaceuticals Inc
26/01/202415:04GlobeNewswire Inc.Processa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/01/202414:30GlobeNewswire Inc.Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesNASDAQ:PCSAProcessa Pharmaceuticals Inc
19/01/202413:45GlobeNewswire Inc.Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerNASDAQ:PCSAProcessa Pharmaceuticals Inc
18/01/202413:45GlobeNewswire Inc.Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock SplitNASDAQ:PCSAProcessa Pharmaceuticals Inc
02/01/202423:06GlobeNewswire Inc.Processa Pharmaceuticals to Present at the Biotech Showcase 2024NASDAQ:PCSAProcessa Pharmaceuticals Inc
29/12/202314:55Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PCSAProcessa Pharmaceuticals Inc
19/12/202315:00GlobeNewswire Inc.Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/12/202315:00GlobeNewswire Inc.Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/11/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the MedInvest Oncology Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/11/202314:15GlobeNewswire Inc.Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and OutlookNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/11/202322:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
13/11/202319:40GlobeNewswire Inc.Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil ThompsonNASDAQ:PCSAProcessa Pharmaceuticals Inc
09/11/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 AmericasNASDAQ:PCSAProcessa Pharmaceuticals Inc
01/11/202313:15GlobeNewswire Inc.Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion LeadersNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/10/202319:08GlobeNewswire Inc.Processa Pharmaceuticals to Present at the ThinkEquity ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202316:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PCSAProcessa Pharmaceuticals Inc
05/10/202316:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/09/202322:09Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PCSAProcessa Pharmaceuticals Inc
06/09/202314:15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
17/08/202314:05GlobeNewswire Inc.Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer CareNASDAQ:PCSAProcessa Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCSA

La tua Cronologia

BIT
FBK
Finecobank
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BC
Brunello Cucinelli
BIT
SPM
Saipem
BIT
G
Generali
BIT
LDO
Leonardo
BIT
MONC
Moncler
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network